Breast cancer treatment is seeing the benefits of a new system that tests new dugs on patients then follows up the trial with surgery to see whether the medicine was effective.

AP photo

Breast cancer treatment is seeing the benefits of a new system that tests new dugs on patients then follows up the trial with surgery to see whether the medicine was effective.

New method quickly tests cancer drugs

By Marilynn Marchione

The Associated Press

0 Comments | Leave a Comment

SAN ANTONIO – A novel way to speed the testing of cancer drugs and quickly separate winners from duds has yielded its first big result: an experimental medicine that shows promise against a hard-to-treat form of breast cancer.

The method involves studying drugs in small groups of people and using advanced statistical techniques to analyze the results as they come in, instead of waiting for all the data to arrive.

Whether the drug, veliparib, ever makes it to market remains to be seen, but it has shown enough potential to advance to final-phase testing aimed at U.S. Food and Drug Administration approval.

Bringing a new cancer drug to market usually takes more than a decade and tests in thousands of patients, and costs more than $1 billion. Companies can’t afford many studies such as that, and patients can’t wait years for potentially life-saving new medicines, said Don Berry, a biostatistician at the M.D. Anderson Cancer Center at the University of Texas.

Researchers testing a drug usually don’t see results until they’re all in, to prevent biasing the study. But several years ago, an unusual partnership decided to try a new way. It involves the National Cancer Institute, the FDA, drug companies, dozens of cancer research centers and charitable foundations.

The study, called I-SPY 2, puts small groups of women on experimental drugs or combinations, then gives them surgery to see what effect the medicines had. The best result is a complete response, where no signs of cancer remain.

Each patient’s results are analyzed as they come in, and advanced statistical methods are used to calculate probabilities that the drug would help in various situations, depending on which women had a complete response.

“This allows us to learn and adapt from each patient as the study goes on,” and results on early participants guide treatment that later ones get, said Dr. Hope Rugo of the University of California-San Francisco. When enough evidence indicates a high probability of success, the drug “graduates” to final-phase testing.